The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Photo of Mattias Ohlsson

Mattias Ohlsson

Professor

Photo of Mattias Ohlsson

Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer : A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice

Author

  • Mariana Reza Felix
  • Mattias Ohlsson
  • Reza Kaboteh
  • Aseem Anand
  • Ingela Franck Lissbrant
  • Jan-Erik Damber
  • Anders Widmark
  • Camilla Thellenberg-Karlsson
  • Lars Budäus
  • Thomas Steuber
  • Till Eichenauer
  • Per Wollmer
  • Lars Edenbrandt
  • Elin Trägårdh
  • Anders Bjartell
Show all

Summary, in English

Background Abiraterone acetate (AA) prolongs survival in metastatic castration-resistant prostate cancer (mCRPC) patients. To measure treatment response accurately in bone, quantitative methods are needed. The Bone Scan Index (BSI), a prognostic imaging biomarker, reflects the tumour burden in bone as a percentage of the total skeletal mass calculated from bone scintigraphy. Objective To evaluate the value of BSI as a biomarker for outcome evaluation in mCRPC patients on treatment with AA according to clinical routine. Design, setting, and participants We retrospectively studied 104 mCRPC patients who received AA following disease progression after chemotherapy. All patients underwent whole-body bone scintigraphy before and during AA treatment. Baseline and follow-up BSI data were obtained using EXINI BoneBSI software (EXINI Diagnostics AB, Lund, Sweden). Outcome measurements and statistical analysis Associations between change in BSI, clinical parameters at follow-up, and overall survival (OS) were evaluated using the Cox proportional hazards regression models and Kaplan-Meier estimates. Discrimination between variables was assessed using the concordance index (C-index). Results and limitations Patients with an increase in BSI at follow-up of at most 0.30 (n = 54) had a significantly longer median survival time than those with an increase of BSI >0.30 (n = 50) (median: 16 vs 10 mo; p = 0.001). BSI change was also associated with OS in a multivariate Cox analysis including commonly used clinical parameters for prognosis (C-index = 0.7; hazard ratio: 1.1; p = 0.03). The retrospective design was a limitation. Conclusions Change in BSI was significantly associated with OS in mCRPC patients undergoing AA treatment following disease progression in a postchemotherapy setting. BSI may be a useful imaging biomarker for outcome evaluation in this group of patients, and it could be a valuable complementary tool in monitoring patients with mCRPC on second-line therapies. Patient summary Bone Scan Index (BSI) change is related to survival time in metastatic castration-resistant prostate cancer (mCRPC) patients on abiraterone acetate. BSI may be a valuable complementary decision-making tool supporting physicians monitoring patients with mCRPC on second-line therapies.

Department/s

  • Nuclear medicine, Malmö
  • Department of Astronomy and Theoretical Physics - Has been reorganised
  • Urological cancer, Malmö
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
  • EpiHealth: Epidemiology for Health

Publishing year

2016

Language

English

Pages

540-546

Publication/Series

European Urology Focus

Volume

2

Issue

5

Document type

Journal article

Publisher

Elsevier

Topic

  • Cancer and Oncology
  • Urology and Nephrology

Keywords

  • Abiraterone acetate
  • Bone metastasis
  • Bone Scan Index
  • Castration-resistant prostate cancer

Status

Published

Research group

  • Nuclear medicine, Malmö
  • Urological cancer, Malmö

ISBN/ISSN/Other

  • ISSN: 2405-4569